INTRODUCTION

Bupropion hydrochloride is a unique aminoketone antidepressant, unrelated to other known antidepressants.\(^1\)\(^-\)\(^3\) It is the only norepinephrine and dopamine reuptake inhibitor (NDRI) currently available in Hong Kong. In view of the variations in drug response due to genetic differences and the lack of local evidence-based treatment guidelines, a consensus meeting was organized to develop guidance for psychiatrists and medical practitioners on the use of bupropion in different psychiatric conditions.

METHODS

A meeting was held on November 10, 2014, in Hong Kong, and the consensus group included 10 local physicians with extensive experience in the management of major depressive disorder (MDD). The literature search was performed in the PUBMED database using combinations of the following keywords: “bupropion,” “major depressive disorder,” “smoking cessation,” and “side effects.” After review, 32 out of 283 references were included to be discussed by the consensus group.
The consensus group utilized the modified Delphi technique to allow formal face-to-face expert focus meeting. After a comprehensive review and discussion, eleven statements on bupropion were finalized and voted anonymously using electronic voting devices. Each statement was rated according to both (a) quality of evidence and (b) practicability of recommendation in Hong Kong. A consensus statement was only accepted if ≥80% voted "A" or "B" for practicability (Table 1).

3 | RESULTS

Statement 1: Besides treatment for major depressive disorder, bupropion is also indicated for seasonal affective disorder and is particularly useful for patients with anhedonia, reduced motivation, weight concern, and sexual dysfunction.

Quality of evidence: I
Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0%

In Hong Kong, bupropion is indicated for the treatment of MDD and seasonal affective disorder. The efficacy and safety profile of bupropion have been demonstrated in several studies. Bupropion resulted in similar effectiveness as compared to sertraline, although the side effects were significantly more common in sertraline-treated patients. In particular, orgasm or sexual dysfunction was less common in bupropion-treated patients. Sexual dysfunction was reported as an adverse event by <1% of the patients, suggesting that bupropion may be the antidepressant of choice in regard to the avoidance of sexual dysfunction.

Bupropion provides greater relief to anhedonia, fatigue, and low energy, which are the most common symptoms associated with MDD patients, occurring in at least 70% of the patients. As bupropion is also associated with weight loss, it will also be particularly useful for patients with weight concerns.

Statement 2: Off-label use of bupropion includes smoking cessation, attention deficit hyperactivity disorder (ADHD), bipolar depression, depression in Parkinson's disease and occasionally for some anxiety disorders.

Quality of evidence: I (III for depression in Parkinson's disease)
Practicability of recommendation: A-83.3%, B-16.7%, C-0%, D-0%, E-0%

The use of bupropion as an aid in smoking cessation was supported by high-quality evidence. It has been shown that bupropion is effective and well tolerated in adult smokers, both healthy and medically ill with cardiovascular disease or chronic obstructive pulmonary disease (COPD). In a longer study, bupropion has also been shown to be able to delay relapse to smoking across 1 year.

Patients suffering from bipolar depression can benefit from bupropion, with a low rate of manic switch, and bupropion can also be useful to relieve adult ADHD symptoms. Accumulating evidence has also shown that bupropion is efficacious in reducing depression-related anxiety symptoms. However, the effect has not been extensively investigated.

Patients with depression in Parkinson's disease could also benefit from the use of bupropion, although no randomized controlled

### TABLE 1 The grading system for each consensus statement during the voting session. (Modified from the Canadian Task Force on the Periodic Health Examination.)

| Quality of evidence | Classification of recommendation | Practicability of recommendation |
|---------------------|---------------------------------|---------------------------------|
| I: Evidence obtained from at least 1 randomized controlled trial. | A: There is good evidence to support the statement. | A: Accept completely. |
| II-1: Evidence obtained from well-designed control trials without randomization. | B: There is fair evidence to support the statement. | B: Accept with some reservation. |
| II-2: Evidence obtained from well-designed cohort or case-control study. | C: There is poor evidence to support the statement, but recommendation made on other ground(s). | C: Accept with major reservation. |
| II-3: Evidence obtained from comparison between time or places with or without intervention. | D: There is fair evidence to refute the statement. | D: Reject with reservation. |
| III: Opinion of respected authorities, based on clinical experience and expert committee. | E: There is good evidence to refute the statement. | E: Reject completely. |
trial has been conducted. Because depression in Parkinson's disease has been linked to cerebral dopaminergic hypoactivity, commonly prescribed antidepressant treatments such as tricyclic antidepressants (TCA), selective serotonin reuptake inhibitor (SSRI), and serotonin-norepinephrine reuptake inhibitor (SNRI), which lack dopaminergic activity, may not be effective. Bupropion, with its intrinsic dopaminergic action, may be a better choice in this aspect.

**Statement 3:** Bupropion is a unicyclic antidepressant with dual action on dopamine and noradrenaline, but has no effect on serotonin.

| Quality of evidence: II-2 |
|---------------------------|
| Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0% |

Bupropion is classified as an atypical antidepressant, where it specifically acts as a dual norepinephrine and dopamine reuptake inhibitor (NDRI) at clinically relevant doses. The inhibition of serotonin uptake by bupropion and its metabolites has been shown to be negligible even at the highest concentration tested.

**Statement 4:** Bupropion is an effective antidepressant as monotherapy, but is also an adjuvant medication in cases of incomplete response to SSRI antidepressants.

| Quality of evidence: I |
|------------------------|
| Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0% |

In case of suboptimal response to the medication, adding bupropion as an augmentation may also be considered. The augmentation of SSRI with bupropion has demonstrated benefits, including greater reduction in the number and severity of symptoms and fewer side effects.

**Statement 5:** Bupropion is generally well tolerated; the most common side effects include dry mouth, headache, and insomnia; it should be avoided at bedtime.

| Quality of evidence: I |
|------------------------|
| Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0% |

The safety profile of bupropion has been studied extensively in thousands of clinical trial subjects and in over 40 million patients who have received bupropion clinically. Bupropion has been shown to be generally well tolerated and resulted in a relativity low rate of discontinuation. Insomnia is usually transient and can be avoided by not taking bupropion near or at bedtime. In addition, the consensus group acknowledged that dry mouth is relatively common in Chinese patients.

**Statement 6:** Bupropion should be used with caution in patients with hypertension or cardiovascular comorbidities. It is not recommended in patients at risk of seizures, eating disorder, psychosis, and closed-angle glaucoma.

| Quality of evidence: I |
|------------------------|
| Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0% |

Cautions should be exercised when prescribing bupropion in patients with hypertension or cardiovascular comorbidities. Although the use of bupropion as a monotherapy has not been associated with effects on blood pressure as compared to placebo in clinical trials, the risk in elevated blood pressure is increased if bupropion is used in a combination therapy with other drugs that also affect the dopaminergic and noradrenergic activity.

Bupropion should not be used in patients with closed-angle glaucoma due to the risk of angle-closure attack. Bupropion is also not recommended in patients that have or had an eating disorder such as bulimia. Similar with SSRI, bupropion is also associated with the risk of seizure, where the rate increases substantially at doses above 450 mg/d. The group acknowledged the suggestion to exclude patients with past history of epilepsy and to screen patients for comorbidities or medications that may lower seizure threshold. Furthermore, to reduce the risk of seizure, bupropion should be started on a low dose and increased gradually to achieve therapeutic effect.

Finally, bupropion is also not recommended in patients with history of psychosis. Bupropion has a potential risk of precipitating or worsening psychosis in selected at-risk populations, since excessive dopaminergic activity are suspected to be linked to the pathogenesis of psychosis.

**Statement 7:** Bupropion should not be used in patients receiving monoamine oxidase inhibitors, and its combination with venlafaxine may lead to a dose-dependent increase in blood pressure.

| Quality of evidence: I (III for combination with venlafaxine) |
|-------------------------------------------------|
| Practicability of recommendation: A-100%, B-0%, C-0%, D-0%, E-0% |

Monoamine oxidase inhibitors (MAOIs) should not be taken together with bupropion because there is an increased risk of hypertensive reactions. A washout period of at least 14 days is required when a patient switches between the two drugs. Moreover, bupropion and its metabolites are CYP2D6 inhibitors, whereas venlafaxine is a known substrate of CYP2D6. Hence, the concomitant use of bupropion and venlafaxine would shift the drug plasma levels toward an increased level of venlafaxine.

**Statement 8:** Smoking and alcohol use do not appear to interact with bupropion, but its serum concentration may be increased by zinc supplement.

| Quality of evidence: II-2 |
|---------------------------|
| Practicability of recommendation: A-83.3%, B-16.7%, C-0%, D-0%, E-0% |

There is no evidence for kinetic interactions between smoking or alcohol with bupropion. Zinc supplement might produce synergistic effects when given in combination with bupropion; physicians should be aware of this interaction.

**Statement 9:** Bupropion overdose rarely results in death but may lead to seizures, hallucinations, delusions, vomiting, and aggressive behavior.
There are contradicting study results regarding the effect of bupropion on the risk to fetal cardiac malformation during the first trimester of pregnancy.30-34 Nevertheless, the consensus group agreed that there is an elevated risk for it. A statistically significant association between bupropion and fetal cardiac malformation was found, although the magnitude of the observed risks was small.30,33 Ideally, the obstetrician and psychiatrist should work together to assess the risk/benefit of using bupropion and counsel the patient on the potential risk for the developing fetus.30

4 | CONCLUSION

The consensus group has unanimously reached an agreement on 11 statements regarding the use of bupropion in Hong Kong. The present consensus statements are developed as general recommendations for medical practitioners and psychiatrists to be practically referred to in clinical settings.

ACKNOWLEDGMENTS

The authors would like to acknowledge the Asian Association of Neuropsychopharmacology (AANP) for supporting the consensus meeting. Medical writing assistance was provided by Best Solution Co. Ltd. and funded by the AANP. This study did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors. The decision to submit the article for publication was made by all members of the consensus group without any commercial influence.

REFERENCES

1. Settle EC, Stahl SM, Batay SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21:454-463.
2. Reimherr FW, Cunningham LA, Batay SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther. 1998;20:5-16.
3. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7:106-113.
4. L instone HA, Tu roff M. The Delphi Method: Techniques and Applications. Boston, MA: Addison-Wesley Publishing Co., Inc.; 2002.
5. GlaxoSmithKline. Wellbutrin XL (Bupropion Hydrochloride) Tablets [Prescribing Information]. Hong Kong, China: GlaxoSmithKline; 2014.
6. Kavousi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997;58:532-537.
7. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. 2001;62:776-781.
8. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
9. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67:853-873.
10. Papakostas GI, N utt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60:1350-1355.
11. Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation (Review). Cochrane Database Syst Rev. 2014;8:CD000031.
12. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59:1007-1024.
13. Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and its various treatments. Med Hypotheses. 2010;75:544-546.
14. Costa FHR, Rosso ALZ, Maultasch H, et al. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr. 2012;70:617-620.
15. Zaluska M, Dyduck A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr. 2011;23:325-327.
16. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159-166.
17. Fava M, Kendler KS. Major depressive disorder. Neuron. 2000;28:335-341.
18. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51:237-254.
19. Kumar S, Kodela S, Detweiler JG, et al. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen Hosp Psychiatry. 2011;33:612-617.
20. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63:181-186.
21. Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol. 2010;30:473-474.
22. Posner J, Bye A, Jeal S, et al. Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol. 1984;26:627-630.
23. Cunha MP, Machado DG, Bettio LEB, et al. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1913-1920.
24. Spiller HA, Ramoska EA, Krenzelok EP, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med. 1994;12:43-45.
25. Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Med J Aust. 2003;178:61-63.
26. Beuhler MC, Spiller HA, Sasser HC. The outcome of unintentional pediatric bupropion ingestions: a NPDS database review. J Med Toxicol. 2010;6:4-8.
27. Finkelstein Y, Hutson JR, Freedman SB, et al. Drug-induced seizures in children and adolescents presenting for emergency care: current and emerging trends. Clin Toxicol (Phila). 2013;23:57-60. https://ispub.com/IJPN/4/1/9799
28. Li R. Bupropion toxicity with unintentional exposure or abuse: more common than you think. B C Med J. 2014;56:445.
29. LoVecchio F, Hilder R, Pitera A, et al. A prospective poison center experience of sustained-release bupropion over 40-months in children. Internet J Pediatr Neonatal. 2003;4(1). http://ispub/JPN/4/1/9799
30. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203(52):e1-e6.
31. Chan BC, Koren G, Fayeze I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932-936.
32. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54:242-246.
33. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf. 2014;23:1066-1075.
34. Patil AS, Kuller JA, Rhee EHJ. Antidepressants in pregnancy: a review of commonly prescribed medications. Obstet Gynecol Surv. 2011;66:777-787.
35. Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468.

How to cite this article: Lee W-K, Au Yeung K-L, Lam H-B, et al. Consensus statements on the clinical understanding and use of bupropion in Hong Kong. CNS Neurosci Ther. 2021;27(Suppl. 1):20–24. https://doi.org/10.1111/cns.13376